Andy Holt

Andy Holt brings more than fifteen years of experience in cell and gene therapy to Cellistic. In his prior roles, he held business development, corporate development and management positions for CDMOs, driving commercial strategy and growth in adeno-associated virus (AAV) gene therapy manufacturing. In his role at Cellistic, Andy leverages his experience in scaling up cell and gene therapy platforms to help Cellistic clients reach their goals in allogeneic cell therapy.